News Natalizumab Improves the Neurological Condition of Multiple Sclerosis Patients Natalizumab Improves the Neurological Condition of Multiple Sclerosis Patients by Patricia Silva, PhD | September 16, 2015 Share this article: Share article via email Copy article link and don't forget this one Results from a recent Brazilian study, published in the journal Arquivos de Neuro-Psiquiatria, revealed that natalizumab is an effective treatment for multiple sclerosis (MS) patients. The study is entitled “Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers“. MS is a demyelinating, inflammatory disease of the central nervous system, presumably with an autoimmune etiopathogenesis. First line therapies developed for the relapsing-remitting form of MS (RRMS) include disease modifying treatments (DMTs), such as interferons (IFNs) beta and glatiramer acetate. However, these treatment options have been shown to be only partially effective, with 20 – 50% of the treated patients experiencing a relapse or disability progression in a short period of time. Natalizumab is a humanized monoclonal antibody that blocks the Ī±-4 integrin, VLA-4, an adhesion molecule present on the surface of leukocytes (white blood cells), inhibiting their migration into the central nervous system. To analyze the demographics and clinical characteristics, as well as the efficacy and safety profile of natalizumab treatment, researchers conduced a retrospective analysis on Brazilian patients with RRMS in two tertiary MS clinical centers in SĆ£o Paulo, Brazil. In total, the team reviewed medical records of 75 RRMS patients treated for at least 12 months with natalizumab (Tysabri). A subgroup analysis was performed to evaluate the efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) ā¤ 3.0 vs patients with EDSS > 3. The EDSS is a quantification method for disability in MS patients, where the higher the score, the higher is the degree of disability. The results showed that RRMS patients treated for at least one year with natalizumab had a 91% reduction in the annualized relapse rate and a general improvement in their neurological disability. The impact of natalizumab treatment was greater in patients with EDSS < 3.0. Overall, natalizumab was safe, although one patient developed progressive multifocal leukoencephalopathy, a life-threatening condition that affects the brain. RELATED:Ā New Multiple Sclerosis Drug May Repair Nerve Demyelination Based on their findings, the research team suggests thatĀ the positive impact of natalizumab treatment on patients with mild neurological disability should prompt neurologists to consider, in cases of treatment failure, an early therapeutic switch to natalizumab, which is currently mostly used as a 3rd line therapy. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags multiple sclerosis, Natalizumab
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8